Published in

BMJ Publishing Group, Annals of the Rheumatic Diseases, 8(72), p. 1375-1381, 2012

DOI: 10.1136/annrheumdis-2012-202405

Links

Tools

Export citation

Search in Google Scholar

Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.

Journal article published in 2012 by Masa Umicevic Mirkov, Jing Cui, Sita H. Vermeulen, Eli A. Stahl, Erik J. M. Toonen, Remco R. Makkinje, Annette T. Lee, Tom W. J. Huizinga, Renee Allaart, Anne Barton ORCID, Xavier Mariette, Corinne Richard Miceli, Lindsey A. Criswell, Paul P. Tak, Niek de Vries ORCID and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: Treatment strategies blocking tumour necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA). However, a significant subset of patients does not respond for unknown reasons. Currently, there are no means of identifying these patients before treatment. This study was aimed at identifying genetic factors predicting anti-TNF treatment outcome in patients with RA using a genome-wide association approach. METHODS: We conducted a multistage, genome-wide association study with a primary analysis of 2 557 253 single-nucleotide polymorphisms (SNPs) in 882 patients with RA receiving anti-TNF therapy included through the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry and the database of Apotheekzorg. Linear regression analysis of changes in the Disease Activity Score in 28 joints after 14 weeks of treatment was performed using an additive model. Markers with p